CLINICAL PRACTICE
Open Public Comment
Open public comment periods allow key stakeholders to review guideline draft recommendation statements to help identify any errors or gaps prior to publication. This best practice guideline development process allows for greater transparency and complies with the National Academy of Medicine (formerly the Institute of Medicine) standards. Open public comment additionally enables AMP to engage with a diverse group of interested stakeholders around the world, provide a higher-quality product to the AMP membership, and facilitate guideline implementation and dissemination efforts.
AMP Guidelines are available for a 2- to 3-week open comment period. Individual reviewers submit their comments anonymously through a SurveyMonkey form. An alternate form may be available for organizations to submit their comments. All comments are reviewed and considered by the subject matter expert guideline development panel. Any changes made to the draft recommendations from the open comment process will be reviewed and approved by the guideline panel. Comments are advisory only and AMP is not required to make any changes based on feedback from open comment. AMP will not respond to reviewers or post responses to comments.
Available for Open Comment
AMP in partnership with the College of American Pathologists (CAP) and the International Association for the Study of Lung Cancer (IASLC) is pleased to announce an open comment period for draft recommendations developed during the update and revision of the evidence-based recommendations originally published in Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the CAP, the IASLC, and the AMP.
The Lung Guideline Update Project is sponsored by CAP, IASLC, and AMP. An Expert Panel was convened in 2021 to perform a systematic literature review and develop the practice guideline recommendations. The Lung Guideline Expert Panel will review and consider all comments received. The open comment format allows the public to review both reaffirmed recommendation statements from the 2018 guideline and new draft recommendations developed based on the systematic literature review.
The open comment period will take place from August 14—September 12, 2024.
The Lung Guideline Update Draft Recommendations were developed based upon a literature search from January 1, 2016 – June 18, 2022. Downloadable copies of the draft recommendations, literature search parameters, and included literature are available for your review. During this open comment period, we will conduct a literature refresh and incorporate any additional findings into the final published recommendations. As such, these recommendations are to be considered in their draft form and subject to change based upon the comments gathered during this open comment period and informed by evidence gathered in the literature refresh.
The Lung Guideline Update Draft Recommendations and literature search information provided here represent time limited information and are not to be distributed, used, or considered as an accurate representation of the CAP/IASLC/AMP Lung Guideline Expert Panel work product(s) after September 12, 2024.
Thank you for contributing your time and expertise to the Lung Guideline Update Draft Recommendations development process during this open comment period. We look forward to your feedback to further enhance the final recommendations.
Project Co-Chairs: Sinchita Roy-Chowdhuri, MD, PhD on behalf of CAP, Sanja Dacic, MD, PhD on behalf of IASLC, and Neal Lindeman, MD on behalf of AMP
